Quest Diagnostics (DGX)

• Market cap: $16.9B
• 1 day: -0.30%
• 5 days: -0.88%
• 1 month: -2.76%
• 3 months: 1.50%
• 6 months: 1.83%
• Year to date: 0.16%
• 1 year: 13.07%
• 5 years: 41.23%
• 10 years: 115.63%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Employees: 48,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

24% more first-time investments, than exits

New positions opened: 94 | Existing positions closed: 76

10% more call options, than puts

Call options by funds: $62.2M | Put options by funds: $56.3M

10% more capital invested

Capital invested by funds: $13.8B [Q2] → $15.1B (+$1.37B) [Q3]

1% more funds holding

Funds holding: 824 [Q2] → 829 (+5) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 287 | Existing positions reduced: 300

2.44% less ownership

Funds ownership: 90.47% [Q2] → 88.02% (-2.44%) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 2 (-2) [Q3]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $165 9% upside
• Avg. target: $175 16% upside
• High target: $185 22% upside

10 analyst ratings

• positive: 7 70%
• neutral: 3 30%
• negative: 0 0%

Leerink Partners Michael Cherny 68% 1-year accuracy 25 / 37 met price target	15% upside $174	Outperform Upgraded	6 Jan 2025
Morgan Stanley Erin Wright 39% 1-year accuracy 9 / 23 met price target	14% upside $172	Overweight Upgraded	17 Dec 2024
B of A Securities Derik De Bruin 68% 1-year accuracy 13 / 19 met price target	20% upside $182	Buy Maintained	13 Dec 2024
Jefferies Tycho Peterson 42% 1-year accuracy 5 / 12 met price target	22% upside $185	Buy Assumed	10 Dec 2024
Piper Sandler David Westenberg 67% 1-year accuracy 26 / 39 met price target	9% upside $165	Neutral Maintained	28 Oct 2024